The biopharmaceutical industry has seen a lot of change in recent years, between new collaborations with supplier and contract development and manufacturing organizations (CDMOs) and accelerated drug delivery times. According to recent research, biopharmaceutical figures are already using digital and analytics for their benefit, with an increase of up to 40% in plant capacity, 20% in lead time, and 15% reduction in conversion costs (1).
With more growth comes more responsibilities, and processes like cell and gene therapy are on the forefront for the latest strategies to overcome the challenges in the manufacturing space.
